EP. 8: Lenvatinib-Based Combinations for Intermediate-/Poor-Risk mRCC
April 21st 2021
Thomas E. Hutson, DO, PharmD, of Texas Oncology, reacts to results demonstrated by the CLEAR study of lenvatinib in combination with pembrolizumab or everolimus for the treatment of metastatic renal cell carcinoma and discusses best practices for educating community oncologists on dosing with lenvatinib.